Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria

Kidney International

Volumn 78, Issue 4, 2010, Pages 363-373

  Kang, Young Sun ^a   Li, Yingjian ^a   Dai, Chunsun ^a   Kiss, Lawrence P ^a   Wu, Chuanyue ^a   Liu, Youhua ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

adriamycin; integrin linked kinase; podocyte; proteinuria

Indexed keywords

ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; DESMIN; DOXORUBICIN; FIBRONECTIN; GELATINASE B; GLUCOSE; INTEGRIN LINKED KINASE; NEPHRIN; PROTEIN ZO1; PUROMYCIN; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA1;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; GLOMERULOPATHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DISEASE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 77955172248     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.137     Document Type: Article

References (49)

1. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-2147.
2. Wiggins RC. The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 2007; 71: 1205-1214.
3. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 2003; 83: 253-307.
4. Tryggvason K, Wartiovaara J. Molecular basis of glomerular permselectivity. Curr Opin Nephrol Hypertens 2001; 10: 543-549.
5. Reiser J, Kriz W, Kretzler M et al. The glomerular slit diaphragm is a modified adherens junction. J Am Soc Nephrol 2000; 11: 1-8.
6. Kerjaschki D. Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 2001; 108: 1583-1587.
7. Durvasula RV, Shankland SJ. Podocyte injury and targeting therapy: an update. Curr Opin Nephrol Hypertens 2006; 15: 1-7.
8. Kanjanabuch T, Ma LJ, Chen J et al. PPAR-gamma agonist protects podocytes from injury. Kidney Int 2007; 71: 1232-1239.
9. Susztak K, Raff AC, Schiffer M et al. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006; 55: 225-233.
10. Wharram BL, Goyal M, Wiggins JE et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005; 16: 2941-2952.
11. Mitu GM, Wang S, Hirschberg R. BMP7 is a podocyte survival factor and rescues podocytes from diabetic injury. Am J Physiol Renal Physiol 2007; 293: F1641-F1648.
12. Yu D, Petermann A, Kunter U et al. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 2005; 16: 1733-1741.
13. Li Y, Kang YS, Dai C et al. Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol 2008; 172: 299-308.
14. Yamaguchi Y, Iwano M, Toyoda M et al. Epithelial-mesenchymal transition as an explanation for podocyte depletion in diabetic nephropathy. Am J Kidney Dis 2009; 54: 653-664.
15. Reidy K, Susztak K. Epithelial-mesenchymal transition and podocyte loss in diabetic kidney disease. Am J Kidney Dis 2009; 54: 590-593.
16. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010; 21: 212-222.
17. Yoganathan N, Yee A, Zhang Z et al. Integrin-linked kinase, a promising cancer therapeutic target: biochemical and biological properties. Pharmacol Ther 2002; 93: 233-242.
18. Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 2005; 5: 51-63.
19. El-Aouni C, Herbach N, Blattner SM et al. Podocyte-specific deletion of integrin-linked kinase results in severe glomerular basement membrane alterations and progressive glomerulosclerosis. J Am Soc Nephrol 2006; 17: 1334-1344.
20. Dai C, Stolz DB, Bastacky SI et al. Essential role of integrin-linked kinase in podocyte biology: bridging the integrin and slit diaphragm signaling. J Am Soc Nephrol 2006; 17: 2164-2175.
21. Teixeira Vde P, Blattner SM, Li M et al. Functional consequences of integrin-linked kinase activation in podocyte damage. Kidney Int 2005; 67: 514-523.
22. Kretzler M, Teixeira VP, Unschuld PG et al. Integrin-linked kinase as a candidate downstream effector in proteinuria. FASEB J 2001; 15: 1843-1845.
23. Guo L, Sanders PW, Woods A et al. The distribution and regulation of integrin-linked kinase in normal and diabetic kidneys. Am J Pathol 2001; 159: 1735-1742.
24. Li Y, Yang J, Dai C et al. Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis. J Clin Invest 2003; 112: 503-516.
25. Wang Y, Wang YP, Tay YC et al. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int 2000; 58: 1797-1804.
26. Dai C, Stolz DB, Kiss LP et al. Wnt/b-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol 2009; 20: 1997-2008.
27. Oloumi A, Syam S, Dedhar S. Modulation of Wnt3a-mediated nuclear beta-catenin accumulation and activation by integrin-linked kinase in mammalian cells. Oncogene 2006; 25: 7747-7757.
28. Koul D, Shen R, Bergh S et al. Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther 2005; 4: 1681-1688.
29. Li Y, Tan X, Dai C et al. Inhibition of integrin-linked kinase attenuates renal interstitial fibrosis. J Am Soc Nephrol 2009; 20: 1907-1918.
30. Legate KR, Montanez E, Kudlacek O et al. ILK, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol 2006; 7: 20-31.
31. Wu C. PINCH, N(i)ck and the ILK: network wiring at cell-matrix adhesions. Trends Cell Biol 2005; 15: 460-466.
32. Han SY, Kang YS, Jee YH et al. High glucose and angiotensin II increase beta1 integrin and integrin-linked kinase synthesis in cultured mouse podocytes. Cell Tissue Res 2006; 323: 321-332.
33. Wu C, Keightley SY, Leung-Hagesteijn C et al. Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity. J Biol Chem 1998; 273: 528-536.
34. Delcommenne M, Tan C, Gray V et al. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci USA 1998; 95: 11211-11216.
35. Zhou BP, Deng J, Xia W et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004; 6: 931-940.
36. Troussard AA, Costello P, Yoganathan TN et al. The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9). Oncogene 2000; 19: 5444-5452.
37. D'Amico M, Hulit J, Amanatullah DF et al. The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways. J Biol Chem 2000; 275: 32649-32657.
38. Tan C, Costello P, Sanghera J et al. Inhibition of integrin linked kinase (ILK) suppresses beta-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC\/\human colon carcinoma cells. Oncogene 2001; 20: 133-140.
39. Matsui I, Ito T, Kurihara H et al. Snail, a transcriptional regulator, represses nephrin expression in glomerular epithelial cells of nephrotic rats. Lab Invest 2007; 87: 273-283.
40. Li Y, Dai C, Wu C et al. PINCH-1 promotes tubular epithelial-to- mesenchymal transition by interacting with integrin-linked kinase. J Am Soc Nephrol 2007; 18: 2534-2543.
41. Mundel P, Reiser J, Zuniga Mejia Borja A et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997; 236: 248-258.
42. Liu Y, Tolbert EM, Sun AM et al. Primary structure of rat HGF receptor and induced expression in glomerular mesangial cells. Am J Physiol 1996; 271: F679-F688.
43. Guo L, Wu C. Regulation of fibronectin matrix deposition and cell proliferation by the PINCH-ILK-CH-ILKBP complex. FASEB J 2002; 16: 1298-1300.
44. Yang J, Shultz RW, Mars WM et al. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 2002; 110: 1525-1538.
45. Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kB signaling. J Am Soc Nephrol 2008; 19: 1741-1752.
46. Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001; 159: 1465-1475.
47. Li X, Yuan H, Zhang X. Adriamycin increases podocyte permeability: evidence and molecular mechanism. Chin Med J 2003; 116: 1831-1835.
48. Hunt JL, Pollak MR, Denker BM. Cultured podocytes establish a size-selective barrier regulated by specific signaling pathways and demonstrate synchronized barrier assembly in a calcium switch model of junction formation. J Am Soc Nephrol 2005; 16: 1593-1602.
49. Rico M, Mukherjee A, Konieczkowski M et al. WT1-interacting protein and ZO-1 translocate into podocyte nuclei after puromycin aminonucleoside treatment. Am J Physiol Renal Physiol 2005; 289: F431-F441.